Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015955 | 0.86 | NPC1 (0.57) | TSHRALDH1A1L3MBTL1GPR119KDM4E | |
| SCHEMBL14247009 | 0.86 | GPR119 (0.46) | OGAGPR119KDM4ENPC1RAB9A | |
| SCHEMBL357797 | 0.84 | AOC3 (0.44) | OGAGPR119KDM4ENPC1RAB9A | |
| SCHEMBL15189865 | 0.84 | GPR119 (0.44) | OGAGPR119KDM4ENPC1RAB9A | |
| SCHEMBL11957018 | 0.84 | GPR119 (0.46) | OGAGPR119KDM4ENPC1RAB9A | |
| SCHEMBL2597089 | 0.84 | OGA (0.42) | OGAGPR119KDM4ENPC1RAB9A | |
| SCHEMBL19450729 | 0.83 | OGA (0.47) | OGAGPR119KDM4ENPC1RAB9A | |
| SCHEMBL26157318 | 0.83 | ACHE (0.53) | TSHRALDH1A1L3MBTL1ACHEMEN1 | |
| SCHEMBL19450519 | 0.81 | GPR119 (0.42) | OGAGPR119KDM4ENPC1RAB9A | |
| SCHEMBL14019242 | 0.81 | HRH4 (0.48) | OGAGPR119KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021005436-A1 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | MANKIND PHARMA LTD. (IN) | 2021-01-14 | — | — | WO | disclosed |
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | US | disclosed |
| WO-2017175066-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| EP-2760855-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AS WELL AS THEIR USE IN TREATING TYPE-2 DIABETES | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-01-16 | — | — | US | disclosed |
| EP-2331503-B1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2013-08-21 | — | — | EP | disclosed |
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-10-27 | — | — | US | disclosed |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018380-A1 | BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS | GPR119, GPR88, GPR84 | TSHR 363/4885ALDH1A1 1357/4885L3MBTL1 4408/4885 |
| US-20100022515-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GCGR, GPR65 | TSHR 926/4885ALDH1A1 2253/4885L3MBTL1 4668/4885 |
| US-20170291894-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | TSHR 566/4885ALDH1A1 1629/4885L3MBTL1 4764/4885 |
| US-20110263557-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR55, NR1H2 | TSHR 1098/4885ALDH1A1 2341/4885L3MBTL1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.